Drug
Guadecitabine clinical trials
Also written SGI-110.
- studies test it
- 30
- open now
- 0
- in phase 3
- 3
- first study started
- 2011
How studies write it
Studies that test it under each name
Development codes
- SGI-110
- 25
Combined with it in one product
Studies by the year they started
30 studies that test it; most in 2017 (9)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 4 |
| 2016 | 4 |
| 2017 | 9 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 14
- Phase 2
- 19
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 23
Astex Pharmaceuticals, Inc. (6) · National Cancer Institute (NCI) (3) · University of Southern California (3) · M.D. Anderson Cancer Center (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · Groupe Francophone des Myelodysplasies (2) · Italian Network for Tumor Biotherapy Foundation (2) · Memorial Sloan Kettering Cancer Center (1)
Often tested with
Tested in the same studies.
Durvalumab (3) · Decitabine and cedazuridine drug combination (2) · Pembrolizumab (2) · Atezolizumab (2) · Ipilimumab (2) · Nivolumab (2) · Belinostat (1) · Mocetinostat (1)
Studies
Open first, then newest update. How each study uses guadecitabine is read from its arms, and is right about nine times in ten.
Testing it · 30
- Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedPhase 1/2National Cancer Institute (NCI)NCT03206047Written as Guadecitabine
- Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional ChondrosarcomaActive, not recruitingPhase 2National Cancer Institute (NCI)NCT04340843Written as Guadecitabine
- Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.Active, not recruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT03220477Written as Guadecitabine
- Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or RelapsedActive, not recruitingPhase 1/2University of Southern CaliforniaNCT02935361Written as Guadecitabine
- Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder CancerActive, not recruitingPhase 1University of Southern CaliforniaNCT03257761Written as Guadecitabine
- Combination Study of Guadecitabine/ASTX727 and PembrolizumabActive, not recruitingPhase 1Royal Marsden NHS Foundation TrustNCT02998567Written as Guadecitabine
- A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney CancerTerminatedPhase 2National Cancer Institute (NCI)NCT03165721Written as SGI-110 (guadecitabine)
- Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell TransplantCompletedPhase 2M.D. Anderson Cancer CenterNCT02684162Written as Guadecitabine
- Guadecitabine in Treating Patients With Higher-Risk Myelodysplastic SyndromesCompletedPhase 2M.D. Anderson Cancer CenterNCT02131597Written as Guadecitabine
- SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)CompletedPhase 1/2Astex Pharmaceuticals, Inc.NCT01261312Written as Guadecitabine
- Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid LeukemiaCompletedPhase 3Astex Pharmaceuticals, Inc.NCT02920008Written as guadecitabine
- SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission InductionCompletedPhase 3Astex Pharmaceuticals, Inc.NCT02348489Written as SGI-110 (guadecitabine)
- Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAsCompletedPhase 3Astex Pharmaceuticals, Inc.NCT02907359Written as Guadecitabine
- SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)CompletedPhase 2Astex Pharmaceuticals, Inc.NCT01752933Written as SGI-110
- Guadecitabine Extension StudyTerminatedPhase 2Astex Pharmaceuticals, Inc.NCT03603964Written as Guadecitabine
- Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedPhase 2Northwestern UniversityNCT02901899Written as Guadecitabine
- Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung CancerCompletedPhase 2Shadia Jalal, MDNCT03913455Written as Guadecitabine
- A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative NeoplasmsCompletedPhase 2Weill Medical College of Cornell UniversityNCT03075826Written as SGI-110
- Study of Durvalumab and Guadecitabine in Advanced Kidney CancerActive, not recruitingPhase 1/2Ajjai Alva, MDNCT03308396Written as Guadecitabine
- Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial CarcinomaActive, not recruitingPhase 2Fox Chase Cancer CenterNCT03179943Written as Guadecitabine
See all 30 studies that test guadecitabine →
Given in every arm · 3 — guadecitabine is usual care beside what is tested
- Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaCompletedPhase 2M.D. Anderson Cancer CenterNCT02096055Written as Guadecitabine
- SGI-110 in Combination With Carboplatin in Ovarian CancerCompletedPhase 2Astex Pharmaceuticals, Inc.NCT01696032Written as SGI-110
- A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)CompletedPhase 1Hoffmann-La RocheNCT02892318Written as Guadecitabine
Codes
What other systems call guadecitabine · ClinicalTrials.gg INT006268
- MeSH (NLM) C580831guadecitabineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 2KT4YN1DP7GUADECITABINEConfirmed FDA, NLM, Wikidata
- Wikidata Q27254880guadecitabineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C95209GuadecitabineOne source FDA
- DrugBank DB11918One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C580831 | guadecitabine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 2KT4YN1DP7 | GUADECITABINE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27254880 | guadecitabine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C95209 | Guadecitabine | One source FDA |
| DrugBank | DB11918 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.